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ABSTRACT
Objective To test the hypothesis that a relative deficiency
in L-arginine, the substrate for synthesis of the
vasodilatory gas nitric oxide, may be associated with the
development of pre-eclampsia in a population at high
risk.
Design Randomised, blinded, placebo controlled clinical
trial.
Setting Tertiary public hospital in Mexico City.
Participants Pregnant women with a history of a previous
pregnancy complicated by pre-eclampsia, or preeclampsia in a first degree relative, and deemed to be at
increased risk of recurrence of the disease were studied
from week 14-32 of gestation and followed until delivery.
Interventions Supplementation with a medical food—
bars containing L-arginine plus antioxidant vitamins,
antioxidant vitamins alone, or placebo—during
pregnancy.
Main outcome measure Development of pre-eclampsia/
eclampsia.
Results 222 women were allocated to the placebo group,
228 received L-arginine plus antioxidant vitamins, and
222 received antioxidant vitamins alone. Women had 4-8
prenatal visits while receiving the bars. The incidence of
pre-eclampsia was reduced significantly (χ2=19.41;
P<0.001) in women randomised to L-arginine plus
antioxidant vitamins compared with placebo (absolute
risk reduction 0.17 (95% confidence interval 0.12 to
0.21). Antioxidant vitamins alone showed an observed
benefit, but this effect was not statistically significant
compared with placebo (χ2=3.76; P=0.052; absolute risk
reduction 0.07, 0.005 to 0.15). L-arginine plus
antioxidant vitamins compared with antioxidant vitamins
alone resulted in a significant effect (P=0.004; absolute
risk reduction 0.09, 0.05 to 0.14).
Conclusions Supplementation during pregnancy with a
medical food containing L-arginine and antioxidant
vitamins reduced the incidence of pre-eclampsia in a

population at high risk of the condition. Antioxidant
vitamins alone did not have a protective effect for
prevention of pre-eclampsia. Supplementation with Larginine plus antioxidant vitamins needs to be evaluated
in a low risk population to determine the generalisability
of the protective effect, and the relative contributions of Larginine and antioxidant vitamins to the observed effects
of the combined treatment need to be determined.
Trial registration Clinical trials NCT00469846.

INTRODUCTION
Pre-eclampsia and eclampsia are among the leading
causes of maternal and neonatal morbidity and
mortality.1 Despite growing knowledge of the pathophysiology of pregnancy induced hypertensive disorders, no preventive measures have been shown to be
effective.2 The underlying cause of pre-eclampsia/
eclampsia is thought to be abnormal placentation,
characterised by defective invasion of trophoblast
cells and remodelling of the uterine vasculature,3
resulting in reduced utero-placental perfusion, which
leads to activation of mechanisms promoting maternal
vasoconstriction and activation or damage of endothelial cells.4 The endothelium is believed to be a primary target of mediators generated by the placenta.
Damage is amplified by other factors such as reactive
oxygen species.5
Nitric oxide is a potent endothelium derived
vasodilator,6 and defective synthesis of nitric oxide
has been documented in pre-eclampsia.7 The main
site of production of nitric oxide is nitric oxide synthase
in endothelial cells, which uses circulating L-arginine
as a substrate. Hence, the local availability of this
amino acid may be critical to the endothelial adaptive
regulatory mechanisms opposing the vasoconstrictors
in pre-eclampsia. L-arginine is considered to be a semiessential amino acid because under increased demands
endogenous synthesis is not sufficient to fulfil
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requirements.8 Moreover, pregnancy has been
reported to be a state of relative arginine deficiency,7
imposed by the increased formation of nitric oxide,
supporting the adaptive vasodilatation of pregnancy,
and use of L-arginine by the fetus.9 Pre-eclampsia is
also associated with increased concentrations of factors
that inhibit nitric oxide production. Concentrations of
asymmetric dimethyl arginine, a competitive inhibitor
of nitric oxide synthase, are raised in women with preeclampsia.10 Concentrations of soluble fms-like tyrosine kinase 1, which antagonises vascular endothelial
growth factor dependent activation of nitric oxide
synthase, have also been shown to be increased in preeclampsia.11 Endoglin, which impairs activation of
nitric oxide synthase mediated by transforming growth
factor β, is also increased.12
In the past, the role of nutrition in the development of
pre-eclampsia has been a subject of considerable discussion. Although little evidence exists to show that dietary
manipulations can prevent pre-eclampsia, the notion
that they might moderate the secondary features of the
syndrome remains in favour.13 Substantial experimental data in animals and humans indicate that L-arginine
could have a beneficial effect on haemodynamics.14-16
Of particular note, an expanding literature documents
that administration of L-arginine improves vascular
function in people with atherosclerosis and peripheral
vascular disease.17-20 The oral administration of L-arginine to patients with cardiovascular disease has not
been associated with any significant adverse side effects.
This includes previous reports in the literature of use of
L-arginine in pregnant women. Facchinetti et al and
Neri et al infused L-arginine into women whose pregnancies were complicated by intrauterine growth retardation and reported reduced myometrial activity.21 22
These observations raised the possibility that supplemental L-arginine in the diet could provide a source of
substrate for nitric oxide synthesis during pregnancy,
which could promote vasodilatation. More clinical studies are needed in this area because we have limited
experience in the use of L-arginine and other nitric
oxide donators for preventing pre-eclampsia, as stated
in the Cochrane review by Meher and Duley.23 On the
other hand, evidence of endothelial damage mediated
by reactive oxygen species has been proposed as
another mechanism of endothelial damage in preeclampsia.24-26 Consequently, antioxidants have been
proposed as prophylactic agents for pre-eclampsia and
several trials with antioxidants including vitamin C and
tocopherols in pre-eclampsia have been published.27-29
At the time this clinical trial was started, insufficient evidence existed for us to discard the use of antioxidants
for prevention of pre-eclampsia. However, recent trials
and Cochrane reviews do not support the use of antioxidants for this purpose.30 31 We did a three arm clinical trial to test the hypothesis that a combination of Larginine and antioxidant supplementation would
reduce the risk of pre-eclampsia in a high risk population in Mexico City.
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METHODS
Study participants
We enrolled pregnant women between 14 and
32 weeks of gestation at high risk of pre-eclampsia
who were receiving prenatal care at the Instituto
Nacional de Perinatologia Isidro Espinosa de los
Reyes in Mexico City between January 2001 and
December 2005. We included patients at increased
risk of pre-eclampsia, which we defined as either a personal history of pre-eclampsia or pre-eclampsia in a
first degree relative. Eligible participants agreed to
have their prenatal care and delivery at the institution
and provide informed consent. We excluded patients
with multiple gestation, known major fetal anomalies
(as defined by ultrasound studies by the fetal medicine
department), diabetes mellitus or gestational diabetes,
pre-existing hypertension, pre-existing renal disease,
collagen vascular disease, cancer or strong family history of cancer in first degree relatives, and pre-existing
maternal disease needing drug treatment. We
excluded women with type 2 diabetes, cancer, or a
strong family history of cancer because the angiogenic
actions of vascular endothelial growth factor are
thought to be mediated, in part, by nitric oxide.32 All
women were screened for gestational diabetes at week
14 and again at week 24 of gestation, according to the
institutional protocol. We decided in advance that if a
woman was diagnosed as having gestational diabetes
after randomisation she would discontinue taking bars
because of the aforementioned safety concerns. However, we included such women in the data analysis. We
excluded patients with autoimmune disease because
peroxynitrites have been implicated in the pathogenesis of tissue damage in autoimmune disease.
Recruitment and randomisation
Staff of the department of obstetrics reviewed prenatal
records to identify patients who might qualify for the
study. A history of pre-eclampsia was confirmed by
review of the patient’s records, and a family history
of pre-eclampsia was based on patients’ self report.
Gestational age was assessed by last menstrual period
and confirmed by a first trimester ultrasound evaluation. The protocol for recruitment included an initial
visit in which suitability for randomisation was evaluated, an invitation to participate was tendered, a complete obstetric and nutritional history was taken, and
written informed consent was obtained. Participants
were randomly assigned to receive one of the three
treatments. The principal investigator made the assignment centrally after the patient had given informed
consent, by using a computer generated code in random size blocks with concealment of allocation by
sealed envelopes.
Each participant in the L-arginine plus antioxidant
vitamins group received two bars a day. The average
consumption of L-arginine in the United States is
around 5.4 g a day,8 so we decided to supplement at
least 100% of this amount in the form of an available
medical food (Heart Bars, Nellson Nutraceutical, CA,
USA). Two Heart Bars a day deliver 6.6 g of L-arginine
BMJ | ONLINE FIRST | bmj.com
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and antioxidant vitamins.33 Table 1 shows the composition of the bars used in the study. Participants in the
antioxidant vitamins alone group received two bars a
day devoid of L-arginine but containing antioxidant
vitamins. Participants in the placebo group received
two placebo bars a day devoid of L-arginine and antioxidant vitamins.
The bars were packaged in similar envelopes that
made them indistinguishable by appearance, and
they were flavoured such that they had the same taste
irrespective of composition. The bars were packed in
boxes containing a sufficient supply for five weeks of
treatment. Only the principal investigator knew the
group codes. We asked participants to consume bars
until the day of delivery. A basal sample of blood was
taken at the randomisation visit, and protein was measured in a 24 hour urine sample before participants
started the consumption of bars.
Clinical follow-up
Participants were scheduled for clinical follow-up
every three to four weeks. Each visit from this point
included the following: (1) Arterial pressure measurement. Measurements of the arterial pressure were
made according to the recommendations of the American Heart Association (AHA) using the auscultatory
method with mercury sphygmomanometers.34 All staff
collecting arterial pressure measurements were certified by external monitors from the AHA, who made
site visits to the hospital. (2) A sample of 10 mL of
venous blood was collected for determination of Larginine concentration. Plasma was separated and
maintained at −80°C until analysis. (3) Participants
were instructed to obtain a 24 hour urine sample the
Table 1 | Composition of Heart Bar
Compound
Total fat
Saturated fat

Content
2.0 g
0.5 g

Polyunsaturated fat

1.0 g

Monounsaturated fat

0.5 g

Trans fat
Cholesterol

0g
10 mg

Sodium

65 mg

Potassium

100 mg

Total carbohydrate

19 g

Dietary fibre

1.0 g

Sugars

12.0 g

Protein
L-arginine

9.0 g
3.3 g

Vitamin C

250 mg

Vitamin E

200 UI

Niacin

25 mg

Vitamin B-6

2.0 mg

Vitamin B-12

4.8 µg

Folate

200 µg

Each bar weighed 35 g and contained 534 kJ (130 kcal); bars for placebo
group were devoid of L-arginine and antioxidant vitamins; bars for
antioxidant vitamins group were devoid of L-arginine.
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day before the next visit. We assessed urine protein by
quantification in 24 hour urine samples with an automated method (DiaSys Diagnostic Systems, Holsheim,
Germany).35 (4) To measure compliance, we gave each
patient a personal diary to record consumption of bars,
which they brought to every appointment. We also
instructed them to keep the empty envelopes of the
consumed bars, which they also brought back at each
appointment. (5) We offered nutritional education and
assessment of nutritional status during pregnancy to all
participants. We instructed them to avoid the consumption of over the counter prenatal antioxidant vitamins and asked about non-study related vitamin
ingestion at each visit.
End points

We defined pre-eclampsia as hypertension (systolic
blood pressure ≥140 mm Hg, diastolic blood pressure
≥90 mm Hg, or both) and proteinuria (>300 mg/24
hours) presenting after 20 weeks of gestation in
women known to be previously normotensive. We
defined eclampsia as non-epileptic convulsions. We
defined mild pre-eclampsia as when hypertension
and proteinuria were present but no evidence of systemic organ damage was detectable. Severe preeclampsia was detected when proteinuria was above
2.0 g/24 hours, blood pressure was ≥160/110 mm
Hg, or both. We also assessed several neonatal end
points, including preterm birth (born before 37 weeks
of gestation), birth weight, small for gestational age
(according to institutional charts), and Apgar scores.
We based the sample size calculation on consideration
of all three two way comparisons (placebo v antioxidant
vitamins alone, placebo v antioxidant vitamins plus
L-arginine, and antioxidant vitamins plus L-arginine v
antioxidant vitamins alone), assuming a 50% proportional reduction in pre-eclampsia in any group compared with placebo, an α error of 0.05, a β error of 0.2,
and a 1:1:1 allocation ratio. We used a Bonferroni correction so that a test specific error (α) of 0.016 (0.05/3)
was used for significance testing of all primary two way
comparisons. We also used the α error of 0.016 in our
sample size estimation. We assumed a prevalence of preeclampsia in the placebo group of 30% (on the basis of
pilot data from our institution).
L-arginine assays

We measured L-arginine concentrations by high performance liquid chromatography after derivatisation
with the o-phthalaldehyde-ethanethiol reagent as
described by Lundsjo et al.36 The derivatised samples
were separated by using a reversed phase Kingsorb 3µ
C18 column (Phenomenex, Torrace, CA) according to
the standard method. We used peak areas for quantification of L-arginine concentrations, using an external
standard as reference. We report values as µM in
plasma. We monitored within assay and between
assay coefficients of variation and maintained them
under 3%.
page 3 of 8
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Table 2 | Baseline characteristics of participants. Values are means (SD) unless stated
otherwise
Placebo
(n=222)

L-arginine
+ vitamins
(n=228)

Vitamins
alone
(n=222)

P value

Age (years)

28.2 (5.1)

28.0 (6.1)

27.6 (5.5)

0.47*

Gestational age at enrolment (weeks)

21.1 (4.7)

20.9 (4.6)

21.1 (5.3)

0.84*

Previous gestation with pre-eclampsia/first
degree relative with pre-eclampsia

211/11

218/10

209/13

0.65†

Median (range) parity

2 (1-9)

2 (1-6)

2 (1-6)

0.09†

Median (range) vaginal deliveries

0 (0-5)

0 (0-3)

0 (0-6)

0.42†

Median (range) previous caesarean sections

1 (0-2)

1 (0-3)

1 (0-3)

0.48†
0.13†

Characteristic

Median (range) abortions

0 (0-5)

0 (0-3)

0 (0-2)

Systolic blood pressure at enrolment (mm Hg)

105.1 (9.8)

105.4 (8.8)

105.6 (8.8)

0.86*

Diastolic blood pressure at enrolment (mm Hg)

68.3 (9.1)

67.2 (8.7)

67.6 (7.9)

0.40*

Plasma L-arginine (µM)

21.9 (8.5)

22.7 (8.3)

21.9 (9.2)

0.52*

Pre-gestational body mass index

26.8 (4.9)

27.5 (5.3)

26.1 (4.1)

0.28*

5

4

6

0.87†

Smoked during pregnancy
*Analysis of variance.
†Kruskal-Wallis test.

Statistical analysis
The Universidad Autonoma de Sinaloa (MAA-V) and
our biostatistics group (SE and MG) did an independent analysis of the data. The analysis was based on
an intention to treat principle. We compared baseline
measures among the treatment groups by using analysis of variance methods and Kruskal-Wallis tests. We
calculated the proportion of participants who developed pre-eclampsia in each treatment group and did
an overall test of equivalence in these proportions by
using a Pearson χ2 statistic test. We calculated absolute
risk reduction and relative risk, including 95% confidence intervals, and statistical significance.37
RESULTS
We approached 696 women (figure. We excluded 24
women because they failed to meet inclusion criteria
(10 patients) or refused to participate (14 women). Six
hundred and seventy-two women met our eligibility
criteria and agreed to participate. Forty-four (6.5%)

women had a direct relative who had developed preeclampsia, and they were equally distributed among
the three arms in this study. Six hundred and twentyeight women had a previous pregnancy complicated
by pre-eclampsia. We allocated 222 women to the placebo group, 228 women received the L-arginine plus
antioxidant vitamins bars, and 222 women received
the bars with antioxidant vitamins alone. The treatment groups were well balanced with regards to baseline characteristics (table 2).
Clinical follow-up was similar among the women
included in the analysis. All groups had a median of 5
(range 2-9) visits during the study (Kruskal-Wallis,
P=0.21). Less than 5% of study visits were missed for
all three groups. In terms of compliance, the placebo
group consumed a mean of 1.1 (SD 0.5) bars a day, the
L-arginine plus antioxidant vitamins group consumed
1.2 (0.4) bars a day, and the vitamins alone group consumed 1.1 (0.43) bars a day (analysis of variance,
P=0.23). The nutritionists developed several strategies
to promote compliance. Briefly, patients were
instructed to mix bars with other foods such as yoghurt,
gelatine, milk shakes, or fruit.
Reported side effects were significantly more frequent in the group consuming L-arginine plus antioxidant vitamins bars than in the placebo group,
including nausea (P=0.019; absolute risk reduction
0.05, 95% confidence interval 0.02 to 0.08; relative
risk 1.25, 1.04 to 1.51); symptoms of dyspepsia
(P=0.04; 0.03, 0.01 to 0.06; 1.34, 1.02 to 1.77); dizziness (P=0.039; 0.03, 0.01 to 0.05; 1.42, 1.02 to 1.97);
palpitations (P=0.019; 0.04, 0.01 to 0.07; 1.36, 1.05 to
1.76); and headache (P=0.01; 0.06, 0.03 to 0.09; 1.26,
1.06 to 1.51). None of these side effects led to a participant dropping out of the study.
One hundred and twenty-five patients discontinued
their assigned treatment. However, we followed them
up until the end of pregnancy and included them analytically in the group to which they were randomised.
Fifty-six women decided to drop out of the study
voluntarily: 18 in the placebo group, 17 in the L-arginine plus antioxidant vitamins group, and 21 in the

Assessed for eligibility (n=696)
Excluded (n=24):
Did not meet inclusion criteria (n=10)
Refused to participate (n=14)
Allocation
Placebo (n=222)
Received allocated intervention (n=222)

L-arginine + vitamins (n=228)
Received allocated intervention (n=228)

Antioxidant vitamins (n=222)
Received allocated intervention (n=222)

Lost to follow-up (n=40):
Diabetes (n=23)
Discontinued intervention voluntarily (n=17)

Lost to follow-up (n=43):
Diabetes (n=22)
Discontinued intervention voluntarily (n=21)

Analysed (n=228)

Analysed (n=222)

Follow-up
Lost to follow-up (n=42):
Diabetes (n=24)
Discontinued intervention voluntarily (n=18)
Analysis
Analysed (n=222)

Flow diagram of trial
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Table 3 | Clinical outcomes
No (%)*

Absolute risk reduction (95%CI); relative risk (95% CI)*

Placebo
(n=222)

L-arginine
+ vitamins
(n=228)

Vitamins
alone
(n= 222)

67 (30)

29 (13)

Total preterm delivery

44 (20)

Spontaneous preterm delivery

L-arginine + vitamins
v placebo

Vitamins alone
v placebo

L-arginine + vitamins
v vitamins alone

50 (23)

0.17 (0.12 to 0.21); 0.42
(0.28 to 0.62) (χ2: P<0.001)

0.07 (0.005 to 0.15); 0.74 (0.54
to 1.02) (χ2: P= 0.052)

0.09 (0.05 to 0.14); 0.56
(0.37 to 0.85) (χ2: P=0.004)

24 (11)

52 (23)

0.09 (0.05 to 0.13); 0.53
(0.33 to 0.84) (χ2: P=0.003)

0.03 (−0.02 to 0.09); 1.18 (0.82
to 1.68) (χ2: P=0.419)

0.12 (−0.08 to 0.17); 0.44
(0.28 to 0.70) (χ2: P<0.001)

13 (6)

12 (5)

15 (7)

0.005 (−0.03 to 0.02); 0.89
(0.41 to 1.92) (χ2: P=0.631)

0.009 (−0.02 to 0.04); 1.15
(0.56 to 2.36) (χ2: P=0.845)

0.01 (−0.04 to 0.14); 0.77
(0.37 to 1.62) (χ2: P=0.386)

Caesarean section

152 (68.4)

155 (67.9)

148 (66.6)

−0.004 (−0.67 to 0.57); 0.99
(0.87 to 1.12) (χ2: P=0.832)

−0.01 (−0.08 to 0.04); 0.97
(0.85 to 1.10) (χ2: P= 0.612)

0.01 (−0.04 to 0.75); 1.01
(0.89 to 1.15) (χ2: P=0.843)

Mean (SD) gestational age at
delivery

38.4 (2.2)

39.0 (1.9)

38.6 (1.9)

0.65 (0.27 to 1.04)† (P=0.001)

0.29 (−0.68 to 0.09)† (P=0.13)

0.35 (−0.7 to 0.004)† (P=0.051)

Sex of baby (F/M)

115/107

117/111

110/112

χ2: P=0.993

χ2: P=0.704

χ2: P=0.780

Primary outcome
Pre-eclampsia or eclampsia
Secondary outcomes

Mean (SD) Apgar score:
1 minute

7.8 (1.1)

8.2 (0.8)

8.0 (0.8)

0.44 (0.24 to 0.64)† (P=0.000)

0.25 (0.04 to 0.47)† (P=0.015)

0.18 (0.01 to 0.36)† (P=0.04)

5 minutes

8.7 (0.7)

8.9 (0.3)

8.9 (0.3)

0.21 (0.10 to 0.33)† (P=0.000)

0.16 (0.05 to 0.46)† (P=0.007)

0.05 (0.02 to 0.12)† (P=0.18)

81, (−15 to 179)† (P=0.1)

2 (−102 to 98)† (P=0.96)

79 (−17 to 175)† (P=0.1)

0.6 (−1.2 to 0.1)† (P=0.10)

0.1 (−0.6 to 0.8)† (P=0.78)

0.7 (0.03 to 1.3)† (P=0.04)

Mean (SD) neonatal weight (g)
Mean (SD) neonatal length (cm)

3070.2 (470) 2988.6 (506) 2990.7 (451)
48.5 (3.0)

47.9 (3.5)

47.8 (2.9)

*Unless stated otherwise.
†Mean difference (95% CI).

antioxidant vitamins alone group. Sixty-nine participants discontinued the use of bars because of the development of gestational diabetes: 24 in the placebo
group, 23 in the L-arginine plus antioxidant vitamins
group, and 22 in the antioxidant vitamins alone group.
Primary end point

Table 3 shows the findings for the primary end point.
The incidence of pre-eclampsia/eclampsia was significantly lower (χ2=19.41; P<0.001) in women randomised to L-arginine plus antioxidant vitamins
compared with placebo (absolute risk reduction 0.17,
0.12 to 0.21). The number needed to treat (NNT) was
5.73 (95% confidence interval 4.0 to 10.0). Women
receiving antioxidant vitamins alone had an observed
benefit, but this effect was not statistically significant
compared with placebo (χ2=3.76; P=0.052; absolute
risk reduction 0.07, 0.005 to 0.15; NNT 13.06, 6 to
200). The incidence of hypertensive disease was also
reduced in the L-arginine plus vitamins group compared with the vitamins alone group (χ2=8.16;
P=0.004). Adding L-arginine to antioxidant vitamins
compared with vitamins alone resulted in a significant
effect on absolute risk reduction (0.09, 0.05 to 0.14;
NNT 10.20, 6 to 36).
As enrolment took place over a wide interval from
14 to 32 weeks of gestation, we assessed the relation
between gestational age at enrolment and development of pre-eclampsia in women who received L-arginine and antioxidant vitamins compared with placebo.
Treatment before 24 weeks reduced the incidence of
pre-eclampsia (relative risk 0.37, 0.23 to 0.58), whereas
treatment after 24 weeks did not (0.64, 0.30 to 1.37).
However, when we estimated the interaction term
BMJ | ONLINE FIRST | bmj.com

between treatment effect and time of first treatment,
we did not find it to be significant (B=0.002; P=0.96)
Secondary end points

The overall rate of preterm birth was also reduced in
women randomised to L-arginine plus antioxidant
vitamins, although this was not because of a reduction
in spontaneous preterm births (preterm premature
rupture of membranes or preterm labour) (table 3).
We found no difference in mean birth weight or in
the proportion of small for gestational age infants.
Other obstetrical complications, including placental
abruption and postpartum haemorrhage, were similar
among treatment groups. No maternal deaths
occurred. Five neonatal deaths occurred in the study,
two in the placebo group and three in the vitamins
group. These deaths were associated with extreme prematurity. We found no differences in plasma concentrations of L-arginine between treatment groups at the
beginning of the study.
The mean plasma concentration of L-arginine was
lower at the first visit in women who later developed
pre-eclampsia (20.5, SD 8.3) compared with those who
did not develop pre-eclampsia (22.6, SD 8.8) (mean
difference 2.01, 95% confidence interval 0.49 to 3.68;
P<0.01). The figures in the web appendix show the
concentrations of L-arginine (fig A) and the diastolic
and systolic blood pressures (fig B) in the different
treatment groups. L-arginine concentrations were
highest in the group receiving bars containing L-arginine, and the diastolic and systolic pressures were also
significantly lower after initial treatment and negatively correlated with L-arginine plasma concentrations.
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DISCUSSION
We observed a significant reduction in the incidence of
pre-eclampsia/eclampsia in pregnant women who
consumed bars containing L-arginine plus antioxidant
vitamins. The results of this trial support the proposed
hypothesis that supplemental L-arginine can reduce
the risk of pre-eclampsia. Consistent with the main
study outcome, a secondary finding of the study was
that the L-arginine plus antioxidant vitamin supplementation resulted in a significant reduction in the
risk of indicated preterm birth compared with placebo.
Methodological considerations and strengths
Endothelial nitric oxide synthase is constitutively
expressed in endothelial cells, and its activity depends
on the level of expression of the enzyme, availability of
the substrate, and concentrations of at least three different inhibitors that have been associated with preeclampsia. Synthesis of nitric oxide thus depends on
the circulating concentration of L-arginine, and adaptive synthesis of nitric oxide in the endothelium is
linked to dietary consumption of this amino acid. Our
central hypothesis was that impaired vasodilatation in
pregnancies complicated by pre-eclampsia could be
prevented by supplementation with L-arginine in the
diet. The existing literature suggests that L-arginine
has direct effects on blood pressure in experimental
animal models, normal humans, hypertensive patients,
women with pre-eclampsia, and healthy pregnant
women.14-22
Consistent with recent research, antioxidant vitamins alone did not show a statistically significant
reduction in the incidence of pre-eclampsia/eclampsia
in our study. Adding L-arginine to antioxidant vitamins resulted in significant protection against the
development of pre-eclampsia/eclampsia. Our trial
was not powered to detect the small difference we
found between the group consuming L-arginine plus
antioxidant vitamins and the group consuming bars
containing only vitamins. An intriguing result is that
supplementing antioxidant vitamins had a statistically
significant effect on reducing mild pre-eclampsia. This
finding is not consistent with the pooled results of the
other clinical trials of antioxidant vitamins, which do
not suggest a benefit from treatment.30 Recently, the
National Institutes of Health’s Maternal-Fetal Medicine Units completed a large trial including several
institutions in the United States, which reached a similar conclusion.31 In addition, detrimental effects of supplemental vitamin C and vitamin E during gestation
have been reported.30 38 39
Limitations of study
The intervention used in this study must be evaluated
in a population of pregnant women at low risk of preeclampsia. This is particularly relevant because we
found a high prevalence of recurrence of pre-eclampsia
in the studied population. Unfortunately, no information is available from other Mexican centres that could
help to identify characteristics associated with this high
recurrence rate compared with centres in other
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countries that have reported lower recurrence of preeclampsia.40 41
At the time we started this clinical trial, no other
commercial presentation for L-arginine was available
other than supplemented bars. However, new products containing the amino acid L-arginine in a more
palatable presentation are emerging. This makes it feasible to propose a population based study of L-arginine
supplementation in larger groups of women with different levels of risk for pre-eclampsia. We did not
include a study arm that consumed only L-arginine,
as the producer could not supply such bars. In addition, we were aware that L-arginine metabolites may
produce deleterious free radicals,42 so we considered
the inclusion of antioxidant vitamins in the same bars
to be beneficial. Unfortunately, our study design could
not define the relative contributions of L-arginine and
antioxidant vitamins to the beneficial effect of the combination on risk of pre-eclampsia. These ingredients
may have had additive effects, or the interaction may
have been synergistic. Further studies are needed to
clarify these relations. Additionally, our trial was powered to detect a 50% reduction in pre-eclampsia and
was thus not designed to detect smaller differences in
risk reduction between L-arginine plus antioxidant
vitamins and antioxidant vitamins alone.
We did not find concerning side effects during the
supplementation of bars. However, caution is needed
in women with peptic ulcer disease, as administration
of L-arginine may worsen their symptoms.
The protective effect for pre-eclampsia may be greatest if L-arginine and antioxidant vitamins are supplemented before 24 weeks of gestation. Although our
study design did not allow a rigorous test of time of
supplementation and outcome, the above noted trend
should be considered in the design of future clinical
trials to evaluate the efficacy of L-arginine supplementation.
Study in context of previous studies
Previous attempts to use L-arginine during pregnancy
were designed to modify the course of established disease, using the amino acid as a hypotensive agent.43
Staff et al showed no effect of L-arginine on clinical
course when used in women with pre-eclampsia
beyond 28 weeks of gestation.44 This is in concert
with our findings, in which women who started treatment beyond 24 weeks of gestation did not seem to
benefit from treatment. Another clinical trial showed
no benefits of arginine supplementation once the disease was established.45 However, preliminary evidence indicates that supplementing L-arginine during
pregnancy may reduce the risk of pre-eclampsia. Germain et al disclosed some initial findings in women at
high risk of pre-eclampsia who received L-arginine
from week 10 of gestation.46 A small clinical trial of Larginine supplementation in women with chronic
hypertension that showed some maternal benefit was
published after we submitted our work for publication,
supporting the potential benefits of this intervention.47
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WHAT IS ALREADY KNOWN ON THIS TOPIC

3

Pre-eclampsia has been shown to be associated with defective vasodilatation

4

Defective synthesis of nitric oxide, a key vasodilator, has been documented in pre-eclampsia

5

Experimental data in animals and humans indicate that supplementation with L-arginine, the
substrate for nitric oxide synthase, has a beneficial effect on arterial pressure

6

WHAT THIS STUDY ADDS

7

In a population of women at high risk of pre-eclampsia, dietary supplementation with Larginine and antioxidant vitamins reduced occurrence of the disease

8

Supplementation with antioxidant vitamins alone did not reduce occurrence of preeclampsia, consistent with previous studies

9

10

Further study is needed to determine whether these results can be replicated and to identify
whether they are due to L-arginine alone or the combination of L-arginine and antioxidant
vitamins
11

Conclusions
Our observations are consistent with the notion that
availability of the substrate for nitric oxide synthesis
(L-arginine) prolongs the latency to development of
pre-eclampsia in a high risk population of women taking the amino acid supplement in the presence of antioxidant vitamins in a medical food. This relatively
simple and low cost intervention may have value in
reducing the risk of pre-eclampsia and associated preterm birth.
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